Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1-3
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N
§ 103 challenge
Y: Claims 1-3
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims Prior to Institution Decision)
IPR Status
IPR Not Instituted Due to Disclaimer